Private equity firms with a significant stake in Skye Bioscience, Inc. (NASDAQ:SKYE) likely disappointed by last week’s 13% decline

Skye Bioscience, Inc. (NASDAQ:SKYE) has been making headlines recently due to its ownership structure and the influence it has on the company’s decision-making process. With private equity firms holding a significant 43% stake in the business, it is clear that these shareholders play a crucial role in shaping the future of Skye Bioscience.

In fact, the top 4 shareholders collectively own 55% of the company, indicating a high level of control and influence over its operations. This ownership breakdown was highlighted last week when private equity firms faced losses as the stock fell by 13%.

Hedge funds also have a stake in Skye Bioscience, owning 12% of the shares. This is significant as hedge funds often try to influence management decisions to create value for shareholders in the short term. The largest shareholder, 5AM Venture Management, LLC, holds 36% of the shares, followed by Versant Venture Management, LLC with 7.2%, and Altium Capital Management LP with 6.4%.

While institutional ownership can provide insight into a company’s credibility in the investment community, it is important to consider analyst recommendations and the company’s historic performance for a more comprehensive understanding of its future prospects.

Overall, the ownership structure of Skye Bioscience reflects a balance between private equity firms, hedge funds, and institutional investors, all of whom have a stake in the company’s success. This dynamic ownership landscape suggests that key decisions are influenced by a diverse group of shareholders, each with their own interests and objectives.